GRI Bio (GRI) Net Cash Flow (2020 - 2026)
GRI Bio (GRI) posted quarterly Net Cash Flow of $2.8 million for Q1 2026, up 261.36% year-over-year from $780103.4 in Q1 2025, and down 32.51% quarter-over-quarter from $4.2 million in Q4 2025.
GRI Bio (GRI) Net Cash Flow (2020 - 2026) Analysis & Trends
GRI Bio's Net Cash Flow history runs 7 years deep, the most recent figure standing at $2.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 261.36% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $7.8 million (up 1059.26% YoY), while the FY2025 annual figure was $3.2 million, down 0.59% from the prior year.
- Net Cash Flow for Q1 2026 stood at $2.8 million, down from $4.2 million in the prior quarter.
- The five-year high for Net Cash Flow was $4.3 million in Q2 2023, with the low at -$1.7 million in Q1 2025.
- The 5-year median for Net Cash Flow is $282000.0 (2024), against an average of $644764.7.
- The sharpest annual moves came in 2023 and 2025: Net Cash Flow tumbled 1668.42% in 2023, then jumped 1381.21% in 2025.
- GRI Bio's Net Cash Flow stood at -$95000.0 in 2022, then sank by 1668.42% to -$1.7 million in 2023, then surged by 116.79% to $282000.0 in 2024, then surged by 1381.21% to $4.2 million in 2025, then plunged by 32.51% to $2.8 million in 2026.
- Business Quant data shows GRI's Net Cash Flow at $2.8 million in Q1 2026, $4.2 million in Q4 2025, and -$1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | -496,000.00 |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -37.14 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 225.59 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -2.83 Bn |
| 10 | GRI Bio | 3.07 Mn | 3.07 Mn | - | -101,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.82 Mn |
| Mar 31, 2026 | 2.82 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Dec 31, 2025 | 4.18 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Sep 30, 2025 | -1.07 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Mar 31, 2025 | -1.75 Mn |
| Dec 31, 2024 | 282,000.00 |
| Dec 31, 2024 | 282,000.00 |
| Sep 30, 2024 | -1.61 Mn |
| Sep 30, 2024 | -1.61 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Jun 30, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Mar 31, 2024 | 2.28 Mn |
| Dec 31, 2023 | -1.68 Mn |
| Dec 31, 2023 | -1.68 Mn |